Skip to content
Open access

Safety and Effectiveness of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder: Interim Analysis of a Post-marketing Surveillance in Japan

Aug 2026 · Neurological Therapeutics · Vol 15, pp. 2509 - 2526 · 0 citations · 23 references
Medicine

TL;DR

The safety profile of inebilizumab was consistent with prior evidence and no new safety concerns were identified, and inebilizumab reduced relapse rates and decreased concomitant use of oral glucocorticoids and immunosuppressants in patients with NMOSD.

Abstract

Inebilizumab is used in Japan for relapse prevention in aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD). Nationwide post-marketing surveillance (PMS) is underway to evaluate the real-world safety and effectiveness of inebilizumab in Japanese patients with NMOSD. This PMS interim analysis assessed safety and effectiveness of inebilizumab in Japanese patients with NMOSD initiating treatment between June 2021 and November 2023, using data through June 2025. The safety analysis set included 228 patients, and the effectiveness analysis set included 224 patients after excluding three patients from N-MOmentum (NCT02200770) and one without confirmed anti-AQP4 antibody positivity. Twenty-one (safety analysis set) and 20 (effectiveness analysis set) patients discontinued treatment. In the safety analysis set, 194 patients (85.1%) were female, and the mean ± standard deviation (SD) age was 54.2 ± 13.1 years. Adverse drug reactions (ADRs) occurred in 74 patients (32.5%); 31 (13.6%) were serious. Common ADRs were infections (14.5%, n = 33); serious infections (5.7%, n = 13) included COVID-19 (1.3%, n = 3), COVID-19 pneumonia (0.9%, n = 2), and urinary tract infection (0.9%, n = 2). Two fatal ADRs (interstitial lung disease, sudden cardiac death) occurred, for which a causal relationship with inebilizumab could not be excluded. In the effectiveness analysis set, the annualized relapse rate (95% CI) decreased from 0.40 (0.33–0.47) per person-year during the 2 years before inebilizumab initiation to 0.10 (0.07–0.14) per person-year after inebilizumab initiation. From baseline to 1 year, the proportion of patients receiving neither concomitant oral glucocorticoids nor immunosuppressants increased from 5.4% to 33.0%, and the mean ± SD oral glucocorticoid dose decreased from 11.7 ± 7.9 mg/day to 4.3 ± 4.7 mg/day. In this interim analysis, the safety profile of inebilizumab was consistent with prior evidence and no new safety concerns were identified. Inebilizumab reduced relapse rates and decreased concomitant use of oral glucocorticoids and immunosuppressants in patients with NMOSD. UMIN000044431.

Read PDF

Similar papers

Sep 2026

Comparative effectiveness of inebilizumab versus conventional immunotherapies in AQP4-IgG-positive NMOSD: a prospective cohort study with time-varying treatment effects.

Inebilizumab was associated with better relapse and disability outcomes than AZA or MMF and compared with RTX, inebilizumab was associated with lower ARR, whereas no significant differences were detected in time to first relapse or disability progression.

Wenjuan Huang, Xin-Tong Zhang, Zhou-Zhou Wang et al. · 0 citations
Open access Aug 2026

Treatment patterns of patients with neuromyelitis optica spectrum disorder switched to inebilizumab in Japan: a claims-based retrospective study

In Japan, several biological agents with distinct mechanisms of action are available for the prevention of relapse in neuromyelitis optica spectrum disorder (NMOSD), including the B cell-depleting agent inebilizumab. Understanding the management of transitions between these agents is crucial for exploring safe sw...

Kenzo Sakurai, Maki Gouda, Toshimichi Mizuno et al. · 0 citations
Open access Oct 2026

Ten Years of Ocrelizumab in Relapsing Multiple Sclerosis

Key Points Question What is the long-term safety and efficacy profile of ocrelizumab in patients with relapsing multiple sclerosis (RMS)? Findings In the OPERA I/II randomized clinical trials including 1656 patients with RMS, treatment with ocrelizumab for up to 10 years led to near-complete and sustained suppression o...

Stephen L. Hauser, Amit Bar-Or, G. Giovannoni et al. · 0 citations
Open access Aug 2026

Inebilizumab in AQP4‐Seropositive NMOSD: One‐Year Follow‐Up From a Multicenter, Real‐World Study

Inebilizumab demonstrated real‐world effectiveness and a manageable safety profile in a diverse population of patients with AQP4‐IgG‐seropositive NMOSD, supporting the findings of the pivotal N‐MOmentum trial.

Meng-Cui Gui, Jiayang Zhan, Wei Li et al. · 0 citations
Open access Aug 2026

Safety and effectiveness of efgartigimod in patients with generalized myasthenia gravis by autoantibody subtype: analysis of post-marketing surveillance in Japan

Efgartigimod for intravenous infusion (efgartigimod-IV) is approved in Japan for generalized myasthenia gravis (gMG) regardless of autoantibody subtypes, whereas the approvals in other countries are restricted to only anti-acetylcholine receptor antibody (AChR-Ab) positive. Post-marketing surveillance was conducted...

Hirofumi Teranishi, Ryohei Aoyagi, Daisuke Harada · 0 citations
Open access Sep 2026

Real-World Safety and Effectiveness of Adalimumab in Patients with Non-Infectious Intermediate, Posterior, or Panuveitis: A Post-Marketing Surveillance Study in Korea.

PURPOSE This post-marketing surveillance study reports the real-world safety and effectiveness of adalimumab (Humira®, AbbVie Inc.) among patients with non-infectious intermediate, posterior, or panuveitis (NIIPPU) in Korea. METHODS The study was conducted at 17 medical centres from January 2018 to July 2020. Safety...

Seung-Woo Choi, Eun Jeen Ryu, Se Joon Woo · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.